Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.…
Nuvectis Pharma, Inc. Q3 2026 Earnings Call Summary
Nuvectis Pharma (NASDAQ: NVCT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 19 employees.
The shares were at 19.39 USD on 20 November 2026, up 215.8% over 52 weeks. Its 52-week range is 5.770 USD to 29.27 USD: the price is 33.8% below the high and 236.0% above the low.
Its market capitalisation is 666.80M USD.
Nuvectis Pharma reports return on equity of -143.6% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 140.71M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 5 analysts cover the stock; their mean price target of 35.40 USD is 82.6% above the current price. The next earnings report is expected on 10 February 2027.